Boston, Massachusetts, United States SV Health Investors appeared to be the VC, which was created in 1993. The main office of represented VC is situated in the Boston. The venture was found in North America in United States.
We can highlight the next thriving fund investment areas, such as Biopharma, Medical. Among the most popular portfolio startups of the fund, we may highlight EBR Systems, AcuFocus, Schweiger Dermatology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The overall number of key employees were 7.
When the investment is from SV Health Investors the average startup value is 10-50 millions dollars. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. Comparing to the other companies, this SV Health Investors performs on 12 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the SV Health Investors, startups are often financed by Split Rock Partners, Polaris Partners, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Split Rock Partners, Novartis Venture Fund, DeNovo Ventures. In the next rounds fund is usually obtained by OrbiMed, Novo Holdings, Clarus Ventures.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Enara Bio | 03 Oct 2024 | London, England, United Kingdom | |||
Spectrawave | $50M | 11 Sep 2024 | Massachusetts, United States | ||
Spineology | $25M | 06 Aug 2024 | St. Paul Park, Minnesota, United States | ||
Brixton Biosciences | $33M | 14 May 2024 | Cambridge, Massachusetts, United States | ||
Miach Orthopaedics | $20M | 02 Apr 2024 | Boston, Massachusetts, United States | ||
Transine Therapeutics | $5M | 28 Nov 2023 | Cambridge, England, United Kingdom | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
Sitryx Therapeutics | $39M | 27 Sep 2023 | Oxford, England, United Kingdom | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States |
– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.
– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Enara Bio | 03 Oct 2024 | London, England, United Kingdom | |||
Spectrawave | $50M | 11 Sep 2024 | Massachusetts, United States | ||
Spineology | $25M | 06 Aug 2024 | St. Paul Park, Minnesota, United States | ||
Brixton Biosciences | $33M | 14 May 2024 | Cambridge, Massachusetts, United States | ||
Miach Orthopaedics | $20M | 02 Apr 2024 | Boston, Massachusetts, United States | ||
Transine Therapeutics | $5M | 28 Nov 2023 | Cambridge, England, United Kingdom | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
Sitryx Therapeutics | $39M | 27 Sep 2023 | Oxford, England, United Kingdom | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States |
